RxDoctor Payments DataLook up a doctor →

Steven Harris, MD

Pulmonary Disease · Austell, GANPI 1346248267

Payments from drug & device makers

$34,853in general payments, 2019–2025

Across 666 payments — averaging $52.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15K
  • Regeneron Healthcare Solutions, Inc.$11K
  • GSK$2K
  • Sanofi$1K
  • Boehringer Ingelheim$833
  • Grifols USA, LLC$628
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$1,0113%
  • Speaking & faculty fees$18,67054%
  • Travel & lodging$2,3777%
  • Food & beverage$12,48836%
  • Education$3081%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,853 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$242,876
Medicare patients
469
Services billed
3,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter736$761,390
Prolastin CAlpha-1-Proteinase Inhibitor24$176,096
Fasenra PenBenralizumab27$153,201
Breztri AerosphereBudesonide/Glycopyr/Formoterol125$120,238
Dupixent PenDupilumab32$117,528
Breo ElliptaFluticasone/Vilanterol194$114,810
TezspireTezepelumab-Ekko26$111,979
NucalaMepolizumab29$106,933
XolairOmalizumab37$68,004
Spiriva RespimatTiotropium Bromide81$62,326
Arnuity ElliptaFluticasone Furoate136$59,252
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr58$48,706
EliquisApixaban17$16,253
Advair HfaFluticasone Propion/Salmeterol32$15,634
SymbicortBudesonide/Formoterol Fumarate30$15,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Arnuity Ellipta, Anoro Ellipta$2,225$1,100,0391,170 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Pulmicort Flexhaler$14,874$251,203193 claims
Grifols USA, LLCProlastin C$628$176,09624 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$833$69,23595 claims
PfizerEliquis$307$16,25317 claims
Johnson & JohnsonXarelto$13$7,58811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →